Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 3/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL409237 | 0.81 | ITGB3 (0.38) | ITGB3ITGA2BKDM4EALDH1A1TSHR | |
| SCHEMBL408997 | 0.73 | USP2 (0.34) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL14654985 | 0.70 | SMN1; SMN2 (0.41) | ITGB3ITGA2BKDM4EALDH1A1TSHR | |
| SCHEMBL20019726 | 0.69 | ATM (0.42) | ITGB3ITGA2BKDM4EALDH1A1TSHR | |
| SCHEMBL15871575 | 0.69 | ATM (0.39) | ITGB3ITGA2BKDM4EALDH1A1TSHR | |
| SCHEMBL23347875 | 0.69 | — | — | |
| SCHEMBL16219483 | 0.66 | ATM (0.48) | ITGB3ITGA2BKDM4EALDH1A1TSHR | |
| SCHEMBL31621419 | 0.66 | SMN1; SMN2 (0.47) | ITGB3ITGA2BKDM4EALDH1A1TSHR | |
| SCHEMBL5605136 | 0.64 | ATM (0.54) | ITGB3ITGA2BKDM4EALDH1A1TSHR | |
| SCHEMBL6493498 | 0.64 | ATM (0.54) | ITGB3ITGA2BKDM4EALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139897-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | SAREPTA THERAPEUTICS, INC. | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139897-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | NSUN2, UPF1, RTCB | ITGB3 2090/4885ITGA2B 2340/4885KDM4E 3213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.